You are here:

Archived: Atomoxetine (Strattera®)


Following a full submission

Atomoxetine (Strattera) is not recommended for use within NHS Scotland for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older or in adolescents. This advice concerns use in children and adolescents only and does not cover use in adults.

Atomoxetine is no more effective than a stimulant preparation against which it has been assessed. Tolerability was similar, though with some differences in the individual adverse events reported. Unlike the available stimulant preparations, it is not a Controlled Drug under the Misuse of Drugs regulations 2001 and there is evidence that it lacks abuse potential.

However, the economic case has not been demonstrated.

The licence holder has indicated their decision to resubmit.

Drug Details

Drug Name: Atomoxetine (Strattera®)
SMC Drug ID: 153/05
Manufacturer: Eli Lilly and Company Ltd
Indication: Attention-Deficit/Hyperactivity Disorder
BNF Category:
Sub Category: 4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 7 March 2005

Current Advice

Resubmission 11 July 2005